Imagine if the rocket scientists at BTA Mgmt had agreed to even...

Imagine if the rocket scientists at BTA Mgmt had agreed to even 10 % royalty ( Gilead fought Roche over tamiflu and got 20 % plus a huge cash amount ) instead of 7 %, too drop the lawsuit with GSK. They will never be forgiven for this incompetent act. PC you suck. You then blamed Molloy for the lawsuit. Unbelievable.

PS Its 10 % royalty in Australia, NZ , SA, Indonesia



‘’The dream turned sour in 2000 when, according to Biota, GSK cut virtually all promotion and other support for Relenza. Relenza now holds only 3 per cent of the estimated US$330 million (A$500 million) global market for neuraminidase inhibitors.
"In the first year [after launch] we gained about half of the market, but by the end of the year something had happened -- Glaxo merged with SmithKlineBeecham. Something changed and they decided to longer support and promote Relenza," said Molloy.
"Relenza was a breakthrough influenza drug that had great potential, but it was effectively abandoned at birth."
Relenza captured the imagination of both the stockmarket and scientists when it was launched in 1999. It was the first drug to be ‘designed’ to lock into the neuraminidase enzyme found on the surface of the influenza virus, preventing the virus from replicating.
The drug was developed by CSIRO scientists and scientists at Biota and the Victorian College of Pharmacy. An effective influenza treatment is one of the holy grails of medicine and Relenza treats both A and B strains of influenza.
"Relenzaeis an excellent drug and a testament to Australian research. We also believe it is superior to its sole competitor, the oral drug Tamiflu," Molloy said.
Because the drug is inhaled, it gets directly to the lungs, and has fewer side effects than Tamiflu. It's also marginally cheaper according to Molloy.
Molloy explained that the motivation behind the lawsuit was to regain Relenza’s value. “The market and many people have written off Relenza. We haven't," he said. ‘’

https://www.biotechnews.com.au/article/19079/biota_sues_gsk_lost_relenza_revenues


http://www.medicalnewstoday.com/articles/66570.php


http://www.dhub.org/object/351966,research